First Patient Enrolled in Ocata Therapeutics’ Phase 2 Study for Dry AMD

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (NASDAQ:OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that the first patient has been enrolled in the company’s Phase 2 clinical trial using Ocata’s proprietary RPE cells in patients with atrophic (dry) age-related macular degeneration (AMD). The purpose of the trial is to evaluate safety and explore […]

Anuncio publicitario

Leer Más "First Patient Enrolled in Ocata Therapeutics’ Phase 2 Study for Dry AMD"